Flexion Therapeutics, Inc.
Feb 28, 2018

Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference

BURLINGTON, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8:05 a.m Eastern Time on Tuesday, March 6, 2018. Investors can access the live webcast and subsequent archived recording of the presentation by visiting the Flexion website at http://ir.flexiontherapeutics.com

About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.

Corporate Contact:

Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194